Showing 601-610 of 698 results for "".
- DELTA TEEN: Positive Results for Delgocitinib in Adolescent Chronic Hand Eczemahttps://practicaldermatology.com/news/delta-teen-positive-results-for-delgocitinib-in-adolescent-chronic-hand-eczema/2471096/Phase 3 data from the DELTA TEEN trial demonstrated that Anzupgo® (delgocitinib) cream achieved significant improvements in symptoms of moderate to severe chronic hand eczema (CHE) in adolescents aged 12–17, according to a news release from the manufacturer. The DELTA TEEN trial was a 16-w
- Study: PLLA-SCA Induces Adipogenesis and Volumization of the Hip Dellhttps://practicaldermatology.com/news/study-plla-sca-induces-adipogenesis-and-volumization-hip-dell/2468575/Injecting poly-l-lactic acid (PLLA-SCA) is a safe and effective method for durable volumization and aesthetic improvement of the hip dell, and may promote adipogenesis and elastogenesis, according to a new study published in Dermatologic Surgery. “People have used Sculptra for years, but w
- Dupilumab Reduces Inflammatory Biomarkers in Pediatric AD: Studyhttps://practicaldermatology.com/news/dupilumab-reduces-inflammatory-biomarkers-pediatric-ad/2467953/Dupilumab significantly reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis (AD), according to results from recent phase 3 trials. Pediatric patients treated with dupilumab demonstrated substantial reductions in key serum biomarkers associated w
- Merck Discontinues Testing of Experimental Skin Cancer Combo Therapyhttps://practicaldermatology.com/news/merck-discontinues-testing-experimental-skin-cancer-combo-therapy/2463022/Merck has announced the termination of the vibostolimab and pembrolizumab coformulation arm in the Phase 3 KeyVibe-010 trial, according to a news release from the company. The trial assessed the combination therapy's efficacy compared to KEYTRUDA alone as adjuvant treatment for patients w
- Analysis: Alopecia Areata Linked with Work Productivity Losseshttps://practicaldermatology.com/news/analysis-alopecia-areata-linked-with-work-productivity-losses/2462430/Results from a new real-world analysis illuminated demographic and clinical characteristics associated with productivity losses in individuals with alopecia areata. “Patients with alopecia areata experience poor health-related quality of life and significant disease burden,” the authors w
- Strength in Numbers: IPC, IFPA, and ILDS Presidents Sign Letter of Commitmenthttps://practicaldermatology.com/news/strength-in-numbers-ipc-ifpa-and-ilds-presidents-sign-letter-of-commitment/2462144/Hervé Bachelez, MD, PhD, President of the International Psoriasis Council (IPC), Hoseah Waweru, MD, President of the International Federation of Psoriasis Associations (IFPA), and Henry W. Lim MD, President of the International League of Dermatological Societies (ILDS) recently signed a le
- Almirall Seeks Proposals to Better Understand Key Pathological Mechanisms of Skin Diseaseshttps://practicaldermatology.com/news/almirall-seeks-proposals-to-better-understand-key-pathological-mechanisms-of-skin-diseases/2462090/Almirall S.A. is calling for proposals to better understand key pathological mechanisms of several skin diseases through AlmirallShare, its open innovation platform. Almirall’s objective through this call is to identify and explore, through collaboration w
- Study: Men With Skin of Color Are More Likely to Die From Melanomahttps://practicaldermatology.com/news/study-men-with-skin-of-color-are-more-likely-to-doe-from-melanoma/2461853/Men with melanoma – and particularly men with skin of color – are more likely to die than women with melanoma, a new study in the Journal of the American Academy of Dermatology shows. "We know that men may be less likely to seek medical care than w
- WCD News: Janssen's Oral IL-23 Blocker Shows Promise in Phase 2b PsO Studyhttps://practicaldermatology.com/news/wcd-news/2461839/Janssen’s novel oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 performed well in the Phase 2b FRONTIER 1 clinical trial of adults with moderate-to-severe plaque psoriasis (PsO), the Company reports. JNJ-2113 is a novel oral IL-23R antagonist peptide that binds w
- ASA Awards: Jon M. Hanifin, MD, Wins David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/asa-awards-jon-m-hanifin-md-wins-david-martin-carter-mentor-award/2461728/The American Skin Association (ASA) announced the recipients of the 2023 David Martin Carter Mentor Award, 2023 George W. Hambrick Award, and the 2023 Research Achievement Awards at the International Societies for Investigative Dermatology (ISID) in Tokyo, Japan. <